Earnings Call · Q2 FY2025·2025-08-07

Q2 25EPS +18.75%·Rev n/aQ1 25EPS +4.76%·Rev n/aQ4 24EPS +65.95%·Rev n/aQ3 24EPS +21.43%·Rev n/a⚠ consensus missing

Arcutis Biotherapeutics, Inc. ARQT

Unidentified Company Representative — Unknown

Frank Watanabe — President and Chief Executive Officer

Todd Edwards — Chief Commercial Officer

Patrick E. Burnett — Chief Medical Officer

Latha Vairavan — Chief Financial Officer

−8.1%1d on move date−8.0% vs SPY3d−7.6%5d+1.8%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ARQT calls or request research access.

More ARQT calls Browse calls Request research access